Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
simvastatin + interferon beta-1a
- Development stage
- Unknown
- Lead developer
- Biogen
- Modality
- Recombinant Proteins and Enzymes, Small Molecules
- Administration
- Oral, Intramuscular
01
Overview
Simvastatin + interferon beta-1a is a combination of a cholesterol-lowering drug of the statin class (simvastatin) and an immunomodulatory protein (interferon beta-1a) used principally in research for the treatment of relapsing-remitting multiple sclerosis. Simvastatin acts as an inhibitor of HMG-CoA reductase, thereby reducing cholesterol synthesis and exerting anti-inflammatory effects. Interferon beta-1a is a recombinant type I interferon that binds to interferon receptors on cell surfaces and modulates immune activity principally by altering cytokine expression and reducing lymphocyte activation. The combination has been evaluated for potential synergistic or additive effects in reducing disease activity in multiple sclerosis, but high-quality evidence from the SIMCOMBIN trial shows the combination does not provide benefit beyond interferon beta-1a alone and may display pharmacological antagonism.
- Brand names
- AvonexZocor
- Other names
- simvastatin and interferon beta-1a
02
Targets
HMGCR (3-hydroxy-3-methylglutaryl-coenzyme A reductase)IFNAR (Immune system modulation via type I interferon receptor)
Beyond the preview
Go deeper on simvastatin + interferon beta-1a.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on simvastatin + interferon beta-1a.